Pulmão

A phase III, open-label, randomized study of MPDL3280A (anti-PD-L1 antibody) in combination with carboplatin - paclitaxel with or without bevacizumab compared with carboplatin -paclitaxel - bevacizumab in chemotherapy naïve patients with stage IV non-squamous non-small cell lung cancer

Contactos do Centro de Ensaio	Instigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Prof. Dr. António Araújo	Recrutamento	2014-003207-30
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Prof. Doutor Henrique Queiroga	Recrutamento	2014-003207-30
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dra. Teresa Almodôvar	Recrutamento	2014-003207-30

* Recrutamento ou Iniciar

A phase III, open-label, multicenter, randomized study evaluating the efficacy and safety of atezolizumab (MPDL3280A, ANTI-PD-L1 ANTIBODY) in combination with carboplatin - paclitaxel or atezolizumab in combination with carboplatin- nab paclitaxel versus carboplatin - nab-paclitaxel in chemotherapy naïve patients with stage iv squamous non-small cell lung cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Prof. Dr. António Araújo	Recrutamento	2014-003208-59
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Prof. Doutor Henrique Queiroga	Recrutamento	2014-003208-59
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dra. Teresa Almodôvar	Recrutamento	2014-003208-59

* Recrutamento ou Iniciar

A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum based doublet as a first line treatment of recurrent or Stage IV PD L1+ non small cell lung cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Prof. Doutor Henrique Queiroga	Iniciar	2015-001537-24
CUF Porto Hospital Estrada da Circunvalação 14341,4100-180 Porto - Portugal	Prof. Doutora Bárbara Parente	Recrutamento	2015-001537-24

* Recrutamento ou Iniciar

A phase III, open-label, randomized study to investigate the efficacy and safety of atezolizumab (anti−PD-L1 antibody) compared with best supportive care following adjuvant cisplatin-based chemotherapy in PD-L1−selected patients with completely resected stage IB−IIIa non−small cell lung cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Prof. Doutor Henrique Queiroga	Iniciar	2014-003205-15
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dr. Júlio Oliveira	Recrutamento	2014-003205-15

* Recrutamento ou Iniciar

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Prof. Dr. António Araújo	Recrutamento	2015-002197-21
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Dra. Gabriela Fernandes	Iniciar	2015-002197-21

* Recrutamento ou Iniciar

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Fundação Champalimaud Centro Champalimaud Avenida de Brasília 1400-038 Lisboa - Portugal	Dr. Nuno Gil	Recrutamento	2015-002894-39

* Recrutamento ou Iniciar

A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar de Vila Nova de Gaia/Espinho Rua Conceição Fernandes, s/n 4434-502 Vila Nova de Gaia - Portugal	Dra. Ana Barroso	Recrutamento	2015-000575-27
Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E R. Prof. Lima Basto 1099-023 Lisboa - Portugal	Dra. Teresa Almodôvar	Recrutamento	2015-000575-27

* Recrutamento ou Iniciar

A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Centro Hospitalar do Porto Largo Prof. Abel Salazar 4099-001 Porto - Portugal	Prof. Doutor António Araújo	Recrutamento	2014-001473-14
Centro Hospitalar de São João Alameda Prof. Hernâni Monteiro 4200-319 Porto - Portugal	Prof. Doutor Venceslau Hespanhol	Recrutamento	2014-001473-14
Fundação Champalimaud Centro Champalimaud Avenida de Brasília 1400-038 Lisboa - Portugal	Dr. Nuno Gil	Recrutamento	2014-001473-14

* Recrutamento ou Iniciar

A phase III, open-label, randomized study of atezolizumab (mpdl3280a, anti−pd-l1 antibody) in combination with carboplatin or cisplatin+pemetrexed compared with carboplatin or cisplatin+pemetrexed in patients who are chemotherapy-naive and have stage iv non-squamous non−small cell lung cancer

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Hospital Beatriz Ângelo Avenida Carlos Teixeira, 3 2674-514 Loures - Portugal	Dra. Margarida Felizardo	Recrutamento	2015-003605-42
CUF Porto Hospital Estrada da Circunvalação 14341,4100-180 Porto - Portugal	Prof. Doutora Bárbara Parente	Recrutamento	2015-003605-42

* Recrutamento ou Iniciar

Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
CUF Porto Hospital Estrada da Circunvalação 14341,4100-180 Porto - Portugal	Prof. Doutora Bárbara Parente	Recrutamento	2012-005201-48

* Recrutamento ou Iniciar

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
CUF Porto Hospital Estrada da Circunvalação 14341,4100-180 Porto - Portugal	Prof. Doutora Bárbara Parente	Recrutamento	2015-001641-89
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Marta Soares	Recrutamento	2015-001641-89

* Recrutamento ou Iniciar

LUME-Meso: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combination with pemetrexed / cisplatin followed by continuing placebo monotherapy for the treatment of patients with unresectable malignant pleural mesothelioma

Contactos do Centro de Ensaio	Investigador Responsável	Estado*	Nº EudraCT
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E Rua Dr. António Bernardino de Almeida 4200-072 Porto - Portugal	Dra. Marta Soares	Recrutamento	2012-005201-48

* Recrutamento ou Iniciar